Strong Dawn K, Lai Amanda, Primmett Dennis, White Colin T, Lirenman David S, Carter James E, Hurley R Morrison, Virji Mumtaz, Ensom Mary H H
The British Columbia Transplant Society, Vancouver, British Columbia, Canada.
Pediatr Transplant. 2005 Oct;9(5):566-73. doi: 10.1111/j.1399-3046.2005.00339.x.
Cyclosporine (CSA; Neoral) is one of the most common immunosuppressants used in pediatric renal transplantation. Research in adult renal transplant recipients has shown that 2-h post-dose concentration (C2) monitoring and limited sampling strategies (LSSs) are better at predicting drug exposure and outcome than trough concentrations (C0). While C0 monitoring is the usual practice in pediatric renal transplant patients, area under the curve (AUC) monitoring has been shown to be superior in terms of predictive ability and outcomes. However, AUC monitoring is impractical and inconvenient in a clinic setting because it involves many blood samples. An LSS provides a reliable alternative. The purpose of this study was to prospectively define an LSS (AUC(0-12)) for CSA monitoring and to test its predictive performance. As well, an LSS (AUC(0-4)) for CSA was developed and its predictive performance tested. Blood samples for CSA concentrations were collected in 29 stable pediatric renal transplant patients prior to (t = 0) and at 0.5, 1, 2, 4, 6, and 8 h following a steady-state morning CSA dose. AUC was calculated by the trapezoidal method; LSSs for AUC(0-12) and AUC(0-4) were determined using multiple regression analysis in 14 patients; and the LSSs' predictive performance was tested in 15 additional patients. Both LSSs require two blood samples. For the LSS (AUC(0-12)), blood samples are required immediately before the dose and 2 h post-dose: AUC(0-12) = 12.45 C0 + 2.17 C2 + 723.16 (r2 = 0.909). For the LSS (AUC(0-4)), blood samples are required at one and 2 h post-dose, AUC(0-4) = 1.17 C1 + 1.85 C2 - 41.00 (r2 = 0.971). The LSSs demonstrated low bias and high precision for both AUC(0-12) and AUC(0-4). Our two-concentration LSSs are accurate and precise predictors that are more clinically useful for our patient population than other LSSs that have been developed for pediatric renal transplant patients. Our study template provides a guide for other centers to develop accurate and precise LSSs specific to their own patient population.
环孢素(CSA;新山地明)是小儿肾移植中最常用的免疫抑制剂之一。对成年肾移植受者的研究表明,给药后2小时浓度(C2)监测和有限采样策略(LSS)在预测药物暴露和结果方面比谷浓度(C0)更具优势。虽然C0监测是小儿肾移植患者的常规做法,但曲线下面积(AUC)监测在预测能力和结果方面已被证明更具优势。然而,AUC监测在临床环境中不切实际且不方便,因为它需要采集多个血样。LSS提供了一种可靠的替代方法。本研究的目的是前瞻性地确定用于CSA监测的LSS(AUC(0-12))并测试其预测性能。此外,还开发了用于CSA的LSS(AUC(0-4))并测试其预测性能。在29名稳定的小儿肾移植患者中,于稳态晨间CSA剂量给药前(t = 0)以及给药后0.5、1、2、4、6和8小时采集CSA浓度的血样。通过梯形法计算AUC;在14名患者中使用多元回归分析确定AUC(0-12)和AUC(0-4)的LSS;并在另外15名患者中测试LSS的预测性能。两种LSS都需要采集两份血样。对于LSS(AUC(0-12)),需要在给药前即刻和给药后2小时采集血样:AUC(0-12) = 12.45 C0 + 2.17 C2 + 723.16(r2 = 0.909)。对于LSS(AUC(0-4)),需要在给药后1小时和2小时采集血样,AUC(0-4) = 1.17 C1 + 1.85 C2 - 41.00(r2 = 0.971)。两种LSS对AUC(0-12)和AUC(0-4)均显示出低偏差和高精度。我们的双浓度LSS是准确且精确的预测指标,对于我们的患者群体而言,比已为小儿肾移植患者开发的其他LSS在临床上更有用。我们的研究模板为其他中心开发针对其自身患者群体的准确且精确的LSS提供了指导。